Companies
Revvity
the LabChip GX platform miniaturizes capillary electrophoresis onto a microfluidic chip for rapid nucleic-acid fragment sizing, an application vendors are actively optimizing for plasmid DNA and mRNA/gene-therapy QC.
- Country
- United States
- Ticker
- NYSE:RVTY
NYSE:RVTY
Commercial
Coverage
| CN | EU | US | |
|---|---|---|---|
| analytics-pat | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Headcount | approximately 11,000 employees worldwide (2025-12-28) | sec.gov · stocktitan.net |
| Revenue | approximately $2.8 billion for 2024E (2024-12-31) medium confidence | s202.q4cdn.com |
| Certification | Many large manufacturing sites are ISO 45001 and 14001 certified | sec.gov · stocktitan.net |
| Regulatory approval | Instruments support FDA 21 CFR Part 11 compliance | revvity.com |
| Production site | State-of-the-art manufacturing facilities for custom chip fabrication and microfluidics medium confidence | revvity.com |
| Capacity | AAV manufacturing capacity from 30mL research-scale to 10 L batches medium confidence | revvity.com |
Independent sources: s202.q4cdn.com · sec.gov · stocktitan.net
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Capillary electrophoresis for biopharma | analytics-pat | Low | → |
| Plate readers for bioproduction | analytics-pat | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.